Nasally administered buserelin inducing complete remission of lung metastases in male breast Cancer

Vorobiof, Daniel; Falkson, Geoffrey

doi:10.1002/1097-0142(19870215)59:4<688::aid-cncr2820590404>3.0.co;2-e

Cited by 23 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other hormonal agents that have been used include ketoconazole, oestrogen, cyproterone acetate, corticosteroids, androgens, progestins, aminoglutethimide and buserelin with or without the anti-androgen flutamide [78,[129][130][131][132][133][134]. The duration of response to these agents varies from 3 months to 12.5 months [133].…”

Section: Systemic Therapymentioning

confidence: 99%

Male breast cancer: a review of clinical management

Agrawal

Ayantunde

Rampaul

et al. 2006

Breast Cancer Res Treat

133

147

View full text Add to dashboard Cite

show abstract

Section: Systemic Therapymentioning

confidence: 99%

Male breast cancer: a review of clinical management

Agrawal

Ayantunde

Rampaul

et al. 2006

Breast Cancer Res Treat

133

147

View full text Add to dashboard Cite

show abstract

“…A variety of agents have been tested, such as estrogen therapy in the form of diethylstilbestrol, 95,96 cyproterone acetate (a synthetic steroid with anti androgenic and progestational activity), 97 medroxy progesterone acetate, 98 androgens, 94,95 and luteinizing-hormonereleasing hormone agonists, alone or in combination with anti androgens. 99,100 Because of the success of tamoxifen for treating both advanced MBC (responses ranged from 25-80%), 92,94,101 and as an adjuvant treatment (5-year diseasefree survival increased from 28% to 56%, and 5-year overall survival from 44% to 61%), 102 tamoxifen was incorporated as the mainstay of hormonal therapy in MBC.…”

Section: Hormonal Therapymentioning

confidence: 99%

Male breast cancer: a gender issue

Nahleh

Girnius

2006

Nat Rev Clin Oncol

View full text Add to dashboard Cite

The incidence of male breast cancer (MBC) is rising; however, mortality due to MBC has not changed, unlike female breast cancer. This lack of change is mostly attributable to a lack of major progress in the understanding and treatment of the disease. The treatment of MBC has been extrapolated from the knowledge of female breast cancer, despite the multiple differences in the pathogenesis, biology and genetics of these two disease entities, especially the differences with regard to the role of male hormones as well as estrogens in MBC compared with female disease. Although major advances in hormonal manipulation for the treatment of breast cancer are being developed, an improved understanding of the potential differences between male and female breast cancer is essential, as this would provide new opportunities for therapeutic intervention and probable improved outcome for MBC. This review aims at highlighting the major differences between male and female breast cancer with an emphasis on hormonal therapy, and discusses some of the recent advances in MBC.

show abstract

“…Daten über den Nutzen eines adjuvanten Einsatzes der Ausschaltung der Hodenfunktion liegen nicht vor. Eine Wirksamkeitsverbesserung scheint im metastasierten Stadium durch zusätzliche Gabe von Antiandrogenen möglich [3,27].…”

Section: Chirurgische Oder Medikamentöse Orchiektomieunclassified

Systemische Behandlung des Brustkrebses des Mannes

Eucker

Kühnl²,

Possinger³

2007

Zentralbl Chir

View full text Add to dashboard Cite

Due to its low incidence there is only few information on optimal systemic therapy of male breast cancer. There are no prospective randomized trials, neither for early breast cancer nor for advanced stages. Retrospective analyses mostly comprise long-term-data from a small number of patients. In terms of epidemiology, cellular receptors or genetics there exist some significant differences between male and female breast cancer. Therefore, the possibility to extrapolate treatment recommendation for male patients from female breast cancer-trials is limited. Despite a high rate of receptor positivity, hormonal therapy seems to be less efficient in men, possibly due to different biological factors. The current standard in endocrine therapy is tamoxifen. It is not known whether tamoxifen therapy is as effective as orchiectomy, but tamoxifen is favoured because of its low side effects. The use of aromatase inhibitors needs to be considered carefully, since aromatization is blocked, but 5-alpha-reductase increases estrogen-like androstanediole. There might be a benefit from additional therapy with GnRH-analoga respectively 5-alpha-reductase inhibitors, but data is not available yet. Combination of GnRH-analoga and antiandrogens does induce tumor remission, but comparison to other endocrine therapies is still lacking. Currently, the efficiency of fulvestrant, an estrogen receptor destructor, is being examined. Cytostatic therapy seems to be as effective as in female breast cancer patients. Nevertheless, convincing prospective trials for the management of early and advanced male breast cancer need to be performed.

show abstract

Nasally administered buserelin inducing complete remission of lung metastases in male breast Cancer

Cited by 23 publications

References 12 publications

Male breast cancer: a review of clinical management

Male breast cancer: a review of clinical management

Male breast cancer: a gender issue

Systemische Behandlung des Brustkrebses des Mannes

Contact Info

Product

Resources

About